Fig. 2
MRD status at MI in PB (a) and at EOI in PB and/or BM (b). Benda bendamustine, BM bone marrow, EOI end of induction, G obinutuzumab, MI mid-induction, MRD minimal residual disease, and PB peripheral blood
Fig. 2 | Leukemia
MRD status at MI in PB (a) and at EOI in PB and/or BM (b). Benda bendamustine, BM bone marrow, EOI end of induction, G obinutuzumab, MI mid-induction, MRD minimal residual disease, and PB peripheral blood
